• CMA is delighted to announce the reappointment of two distinguished industry leaders – Andrew O'Keefe and Nick Mann – to its Board of Directors and to welcome four esteemed new Directors.

• 
  

• 
  

• 
  

• Interim President

  With over two decades of experience in the complementary medicine and pharmaceutical sectors, Andrew O'Keefe's expertise and leadership are pivotal in steering CMA toward continued success.

  Following the retirement of CMA’s President, Ben Rowe, Andrew has assumed the role of interim President, emphasising his dedication to upholding CMA's values and objectives. Recognising Ben Rowe's significant contributions as CMA President, Andrew O'Keefe expressed, "I am honoured to step into this role and build upon the foundation laid by Ben, ensuring the continued success of CMA."

  Interim Vice President

  Rachel Carter has been appointed interim Vice President, succeeding Paula Hann’s stellar Vice Presidency. Rachel's dedication and experience position her to make significant contributions to the organisation's leadership, further strengthening CMA's commitment to excellence and strategic objectives.

  Innovation and Expansion

  With over three decades of senior leadership experience in sales, marketing, and general management across Australia and Southeast Asia, Nick Mann continues to drive innovation and strategic expansion. His reappointment underscores his commitment to advancing CMA's interests and furthering the growth of Australia's complementary medicines industry.

  Dynamic Focus

  CMA welcomes four new Directors, each bringing diverse perspectives, extensive industry knowledge, and a shared passion for advancing the complementary medicines sector.

• 
  

• Gladys Peters, with a wealth of expertise gained over two decades in leading organisations within the over-the-counter medicine, personal and skin care, and food and beverage sectors, brings extensive leadership in consumer healthcare. Her strategic vision will contribute to CMA's ongoing success.

• 
  

• Alastair Symington, an accomplished executive, brings a wealth of experience in global markets to the CMA Board. His valuable insights will be crucial in navigating the ever-evolving landscape of complementary medicines, both domestically and overseas.

• 
  

• Fiona Scrymgeour, a highly experienced, results-oriented, and innovative Marketing Director, brings a wealth of knowledge and a dedicated commitment to excellence. Her strategic insight will be pivotal in shaping CMA's future endeavours.

• 
  

• Natasha Flynn, former CMA Membership Development Manager, joins the board as a dynamic and experienced leader in complementary medicines. Her focus on leadership, innovation, and sustainable growth aligns seamlessly with our vision, demonstrating dedication to fostering a dynamic and progressive industry.

These appointments join a dynamic, focused Board of Directors with diverse, high-level talent required to support CMA's members best, deliver on the organisation's strategic goals, and propel CMA toward success in its multifaceted mission.

Expressing his enthusiasm for the new board appointments, CMA CEO John O'Doherty stated, "We warmly welcome these outstanding individuals to the CMA Board, where their diverse backgrounds, extensive experience, and commitment to advancing the complementary medicines industry are invaluable.”

“Together, we aim to drive industry growth within a framework of best practice regulation, integrating complementary medicines into preventive health policy to ensure the sustained success of CMA. The collective knowledge of our directors positions us to navigate the dynamic landscape of complementary medicines, aligning with our strategic direction and the Healthy People, Healthy Future plan for continued industry excellence."